Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
ConclusionsSingle-agent pembrolizumab has modest efficacy as a salvage therapy in ACC regardless of the tumor ’s hormonal function, microsatellite instability status, or programmed cell death ligand-1 status. Treatment was well tolerated in most study participants, with a low rate of severe adverse events.Trial registrationClinicalTrials.gov identifier:NCT02721732, Registered March 29, 2016.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Adrenocortical Carcinoma | Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Hormones | Immunotherapy | Study | Women